Skip to main content
. 2020 Dec 9;8(12):e3274. doi: 10.1097/GOX.0000000000003274

Fig. 5.

Fig. 5.

Examples of the sustained efficacy of AFU in the nasolabial folds (A, B) and AFFL in crow’s feet (C, D). Neither patient was reinjected at D180 or D270. Panel A: Day 0, nasolabial folds. Panel B: Day 540, nasolabial folds. Panel C: Day 0, crow’s feet. Panel D: Day 540, crow’s feet.